US Stock Market Closed

Dashboard

ACADIA Pharmaceuticals, Inc. (ACAD)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

B

Management & Equity

S

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

CEO

Stephen R. Davis

Employees

503

Industry

Neurology Biopharmaceuticals

Sector

Healthcare

Headquarters

San Diego

Exchange

NASDAQ

Summary Stats

Market Cap

2.92B

Revenue

512M

Net Income

-205M

EPS

-$1.27

Price-to-Earnings

-14.21

Price-to-Book

6.72

Debt-to-Equity

0.41

News

Analyst Ratings

Price targets projected by 18 analysts

High

$70.00

Average

$59.61

Low

$42.00

Ratings calculated by 18 analysts

Buy

17

Hold

1

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q2 2022

Last Earnings

Above by $0.04

Actual

-$0.21 +16.0%

Consensus

-0.25

Report Date

Year Ago

-0.27

Year Ago Change %

Up 22%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites